Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.

In a report released on November 20, Patrick Roquas from Kepler Capital maintained a Buy rating on Origin Enterprises plc, with a price target of €...

Kepler Capital  Remains a Buy on Origin Enterprises plc (OGN)

Canaccord Genuity analyst Salvatore Verdoliva reiterated a Buy rating on Origin Enterprises plc yesterday and set a price target of €5.00. The comp...

Origin Enterprises plc (OGN) Gets a Buy from Canaccord Genuity

Origin Enterprises plc ( ($GB:OGN) ) has shared an announcement. Origin Enterprises plc has announced the transfer of 2,754 treasury shares to fulf...

Origin Enterprises Transfers Treasury Shares to Fulfill Incentive Plan

In a report released on November 19, Torsten Sauter from Kepler Capital maintained a Buy rating on Logitech, with a price target of CHF105.00. The ...

Kepler Capital  Reaffirms Their Buy Rating on Logitech (LOGI)

In a report released today, Joern Iffert from UBS maintained a Buy rating on Logitech, with a price target of CHF100.00. According to TipRanks, Iff...

UBS Keeps Their Buy Rating on Logitech (LOGI)

Goldman Sachs analyst Gustavo Miele maintained a Buy rating on Cogna Educacao S.A. on November 18 and set a price target of BRL4.00. According to T...

Cogna Educacao S.A. (COGN3) Receives a Buy from Goldman Sachs

Origin Enterprises plc ( ($GB:OGN) ) has shared an announcement. Origin Enterprises plc announced that The Goldman Sachs Group, Inc. has reduced it...

Origin Enterprises Announces Change in Shareholding

Organon & Co. ( ($OGN) ) has released its Q3 earnings. Here is a breakdown of the information Organon & Co. presented to its investors. Organon & C...

Organon & Co. Reports Modest Q3 Revenue Growth

Organon ( ($OGN) ) just unveiled an announcement. On November 3, 2025, Grace Puma announced she will not seek re-election at Organon & Co.’s 2026 A...

Grace Puma to Step Down from Organon Board

An update from Orogen Royalties ( ($TSE:OGN) ) is now available. Orogen Royalties Inc. has announced the grant of 2,000,000 incentive stock options...

Orogen Royalties Grants 2 Million Stock Options Under Equity Plan

In a report released yesterday, Lucas Glemser from Berenberg Bank maintained a Buy rating on Logitech, with a price target of $138.00. The company’...

Logitech (LOGI) Gets a Buy from Berenberg Bank

In a report released today, Matt McCartney from Wedbush maintained a Buy rating on Logitech, with a price target of $135.00. The company’s shares o...

Current Quarter	$0.85	Next Quarter	$NA
Current Year	$3.62	Next Year	$3.78
QoQ Growth	NaN%	YoY Growth	+4.4%
3Y EPS CAGR	-14.3%	Target Price	$10.33
Consensus	Buy	Upside	+43.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OGN	$7.20	+0.98%	5.62M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OGN	$7.20	+1.0%	5.62M
3
4
5
6

OGN

OGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Organon & Co. Data in Excel

Get Organon & Co. Data in Excel